enGene Therapeutics Inc. 8-K

What Happened
enGene Therapeutics filed an 8-K on May 7, 2026 reporting two material items: (1) an Amended and Restated Employment Agreement between its subsidiary enGene USA and Dr. Hussein Sweiti, effective May 6, 2026; and (2) a press release and slide presentation disclosing interim clinical data for the pivotal cohort of its Phase 2 LEGEND trial of detalimogene voraplasmid (detalimogene, previously EG-70) in high‑risk, BCG‑unresponsive patients with carcinoma in situ (CIS) with or without papillary disease. The company also announced a May 7, 2026 conference call to discuss the interim data.

Key Details

• Dr. Hussein Sweiti’s amended compensation: annual base salary of $561,750 and an annual bonus opportunity of 40%; eligible to participate in employee benefit plans.
• Effective May 6, 2026; amendment allows, on or after June 1, 2026, Dr. Sweiti to resign for any reason or no reason with five business days’ prior written notice and still receive his post‑termination severance benefits.
• The amendment expressly waives any obligation of Dr. Sweiti to repay the value of his prior sign‑on bonus.
• The company issued a press release (Exhibit 99.1) and furnished a slide presentation (Exhibit 99.2) with new interim clinical data from the Phase 2 LEGEND pivotal cohort; a conference call was held May 7, 2026.

Why It Matters

• Executive terms: Changes to Dr. Sweiti’s employment clarify compensation and increase his post‑termination flexibility while preserving severance and waiving repayment of the sign‑on bonus—details investors may consider when assessing management stability and compensation practices.
• Clinical development: Publication of interim Phase 2 LEGEND data is material to the company’s development progress for detalimogene in BCG‑unresponsive CIS patients; such updates can affect the regulatory strategy, timelines, and investor sentiment.
• Where to find more: The full Sweiti Employment Agreement will be filed as an exhibit to the company’s Form 10‑Q for the period ended April 30, 2026; the May 7 press release and slide deck are attached as Exhibits 99.1 and 99.2 to the 8‑K.